ArriVent BioPharma Inc [AVBP] stock is trading at $16.95, down -2.53%. An important factor to consider is whether the stock is rising or falling in short-term value. The AVBP shares have lost -12.85% over the last week, with a monthly amount drifted -22.50%, and not seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
Previously, B. Riley Securities started tracking the stock with Buy rating on March 20, 2025, and set its price target to $37. On March 10, 2025, Guggenheim initiated with a Buy rating and assigned a price target of $45 on the stock. Oppenheimer started tracking the stock assigning a Outperform rating and suggested a price target of $35 on July 22, 2024. H.C. Wainwright initiated its recommendation with a Buy and recommended $25 as its price target on April 30, 2024. Jefferies started tracking with a Buy rating for this stock on February 20, 2024, and assigned it a price target of $35. In a note dated February 20, 2024, Goldman initiated an Buy rating and provided a target price of $27 on this stock.
ArriVent BioPharma Inc [AVBP] stock has fluctuated between $15.47 and $36.37 over the past year. Currently, Wall Street analysts expect the stock to reach $33 within the next 12 months. ArriVent BioPharma Inc [NASDAQ: AVBP] shares were valued at $16.95 at the most recent close of the market. An investor can expect a potential return of 94.69% based on the average AVBP price forecast.
Analyzing the AVBP fundamentals
To continue investigating profitability, this company’s Return on Assets is posted at -0.51, Equity is -0.55 and Total Capital is -0.59. Upon thorough examination of the company’s fundamental financial framework, it becomes apparent that the debt-to-equity ratio stands at 0.0.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 16.14 points at the first support level, and at 15.33 for the second support level. However, for the 1st resistance point, the stock is sitting at 17.72, and for the 2nd resistance point, it is at 18.48.
Ratios To Look Out For
For context, ArriVent BioPharma Inc’s Current Ratio is 12.74. On the other hand, the Quick Ratio is 12.74, and the Cash Ratio is 5.74.
